🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesPrediabetic and scared - will this actually prevent diabetes? — need advice Page 2

Prediabetic and scared - will this actually prevent diabetes? — need advice

JessicaH_TX Wed, Feb 18, 2026 at 8:37 AM 21 replies 910 viewsPage 2 of 5
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Feb 18, 2026 at 1:49 PM#6
JessicaH_TX said:
HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very…

Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:

HOMA-IR = (fasting insulin × fasting glucose) ÷ 405

My numbers: Baseline HOMA-IR = 5.9 (insulin resistant) → Current = 1.5 (insulin sensitive)

Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.

1 21steve_okc
Reply Quote Save Share Report
JenPlateau
Member
234
890
Nov 2024
Missouri
Feb 18, 2026 at 3:51 PM#7

A narrower follow-up, since the general answer is now clear:

What would you measure differently if you were starting again?

50 20TrialNerd_Beth, HPLC_Greg, LibrarianMeg and 47 others
Reply Quote Save Share Report
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Feb 18, 2026 at 5:53 PM#8
PeptideChemSF said:
Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking: HOMA-IR = (fasting…

My labs after 9 months on glycaemic control: A1C 6.2%, fasting glucose 77 mg/dL, fasting insulin 4 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 6.9% and fasting glucose was 122 mg/dL. The improvement has been dramatic and consistent.

Last edited: Feb 18, 2026 at 10:53 PM
49 19maya_sedona, stefan_berlin, Dr.EM_Chicago and 46 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
JessicaH_TX
Senior Member
4,123
13,456
Dec 2023
Houston, TX
Feb 18, 2026 at 7:55 PM#9
PeptideChemSF said:
Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking: HOMA-IR = (fasting…

Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include:

BiomarkerAssociationEvidence Level
Baseline BMIHigher BMI → greater absolute weight lossStrong
Fasting insulinHigher insulin → better responseModerate
GLP1R gene variantsrs6923761 → variable responsePreliminary
Baseline hsCRPHigher CRP → greater CV benefitModerate
Early weight loss (4 wk)≥3% at 4 wks → strong predictor of ≥10% at 68 wksStrong

The 4-week early responder criterion is the most clinically actionable: if you haven't lost ≥3% by week 4 at a therapeutic dose, discuss optimization strategies with your provider.

Last edited: Feb 18, 2026 at 11:55 PM
48 18Dr.NephBHM_UK, kim_atl_prep, sarah_TO and 45 others
Reply Quote Save Share Report
pat_auckland
Member
345
1,567
Jun 2024
Auckland, NZ
Feb 19, 2026 at 5:39 AM#10
TrialTracker_MD said:
My labs after 9 months on glycaemic control: A1C 6.2%, fasting glucose 77 mg/dL, fasting insulin 4 uIU/mL.

Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:

TestBaselineMonth 3Month 6Month 12
Glucose (fasting)1241028886
Insulin (fasting)201686
HOMA-IR4.53.51.61.3
Uric Acid8.26.45.55.0

The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 4.5 to near 1.0 is a metabolic transformation.

16 14dan_philly, MeganSA_TX, LarryQC_SD and 13 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register